PIP Search Page

Displaying 241 - 260 of 773

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area Sort ascending	Decision Type	Compliance Check	Compliance outcome	Date Published
MHRA-100066-PIP01-21-M01 (update)	efgartigimod alfa	Treatment of myasthenia gravis	Vyvgart Vyvgart Vyvgart	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		19/12/2023
MHRA-100975-PIP01-23-M01 (update)	ERENUMAB	Prevention of migraine headaches	Aimovig Aimovig Aimovig	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		19/12/2023
MHRA-100043-PIP01-21-M01 (update)	zilucoplan	Treatment of myasthenia gravis	Zilbrysq Zilqivik	Neurology Other: Complement inhibitor for treatment of the autoimmune disease myasthenia gravis	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		19/12/2023
MHRA-100482-PIP01-22-M01 (update)	acetyl-L-leucine ((s)-(acetylamino)-4-methylpentanoic acid)	Treatment of Niemann-Pick disease type C	Not available at present	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		19/12/2023
MHRA-100949-PIP01-23-M01 (update)	Delandistrogene moxeparvovec	Treatment of Duchenne muscular dystrophy	Not available	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		19/12/2023
MHRA-101016-PIP01-23	ublituximab	Treatment of multiple sclerosis	Briumvi Briumvi	Neurology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		20/12/2023
MHRA-100336-PIP01-21-M02 (update)	Soticlestat	Treatment of Dravet Syndrome Treatment of Lennox-Gastaut Syndrome		Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/01/2024
MHRA-100547-PIP01-22-M02 (update)	PEGINTERFERON BETA-1A	Treatment of multiple sclerosis.	Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy Plegridy	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/01/2024
MHRA-101030-PIP01-23	Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) (SAR443820)	Treatment of Amyotrophic lateral sclerosis		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/01/2024
MHRA-101287-PIP01-23	SUMATRIPTAN NAPROXEN SODIUM	Treatment of migraine headaches	Suvexx 85 mg/500 mg film-coated tablets FI, DK, HU, NO, SE: Nomigrin EE, LT, LV: Migsun PL: Frimig Duo	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-100594-PIP01-22	N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethyl-phenyl]-3,3-dimethylbutanamide	Treatment of focal onset seizures		Neurology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		30/04/2024
MHRA-100103-PIP01-21	Rozanolixizumab	Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease	Not available at present	Neurology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		30/04/2024
MHRA-101094-PIP01-23	Givinostat	Treatment of Duchenne muscular dystrophy		Neurology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	Yes	Partial Compliance Check Granted	30/04/2024
MHRA-101115-PIP01-23	Sodium ({(2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1)	Treatment of Amyotrophic lateral sclerosis	Not available at present	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		30/04/2024
MHRA-100462-PIP01-22-M02 (update)	FENFLURAMINE HYDROCHLORIDE	Treatment of Dravet Syndrome	Fintepla Fintepla Fintepla Fintepla Fintepla	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/04/2024
MHRA-100468-PIP01-22-M02 (update)	EPTINEZUMAB	Prevention of migraine headaches	Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti Vyepti	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/04/2024
MHRA-100046-PIP01-21-M04 (update)	cenobamate	Treatment of epilepsy	Ontozry Ontozry Xcopri Ontozry	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/04/2024
MHRA-100037-PIP01-21-M02 (update)	ponesimod	Treatment of Multiple Sclerosis	Ponvory	Neurology Other: Autoimmune disease/dysfunction	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/04/2024
MHRA-100099-PIP01-21-M04 (update)	BRIVARACETAM	Treatment of paediatric epilepsy syndromes Treatment of neonatal seizures	Briviact (in Italy: Nubriveo)	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/04/2024
MHRA-100105-PIP01-21-M01 (update)	ALPRAZOLAM	Treatment of epileptic seizures		Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		30/04/2024

Download XLSX